UTT’s proprietary biodegradable sponge aims to enable topical delivery of existing medications for various urinary conditions. The sponge is designed to be inserted into the bladder via catheter, where it expands. This approach is being explored for potential applications in: bladder inflammation, overactive bladder, urinary incontinence, and bladder cancer. The sponge-based system is adaptable for use with different types of medications, including: chemotherapy agents, antibiotics, antimuscarinics, and mirabegron. This technology aims to offer a new method for delivering medications directly to the bladder, potentially allowing for localized treatment approaches.

UTT is developing a non-surgical alternative for prostate tumors using a proprietary liquid gel technology. The concept involves dissolving a chemotherapy agent into the gel, which is then designed to be injected into the prostate. The gel is intended to release the chemotherapy agent over a period of several days. This method aims to expose prostate tumors directly to the chemotherapy gel. UTT is exploring this technology as a potential alternative to surgical interventions for prostate conditions.